Black Diamond Therapeutics
BDTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +13.6% in FY2025
Mark A. Velleca, M.D., Ph.D. is the CEO of Black Diamond Therapeutics and was paid $2.2M in FY2025 (Dec), down 22%.
Pay$100 in the stock at the end of FY23 → $86
Executives3
See all- 1Mark A. Velleca, M.D., Ph.D.President and Chief Executive OfficerFY2025
- 2Sergey Yurasov, M.D., Ph.D.Chief Medical OfficerFY2025
- 3Brent Hatzis-Schoch, Esq.Chief Operating Officer and General CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allBlack Diamond Therapeutics paid its 3 named executives $4.9M in total in FY2025 (Dec). CEO Mark A. Velleca, M.D., Ph.D. was paid $2.2M of that.
| Name | |||
|---|---|---|---|
| Mark A. Velleca, M.D., Ph.D.President and Chief Executive Officer | Not disclosed | ||
| Sergey Yurasov, M.D., Ph.D.Chief Medical Officer | |||
| Brent Hatzis-Schoch, Esq.Chief Operating Officer and General Counsel | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Black Diamond Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Samarth Kulkarni, Ph.DLead independent director · 6 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Garry E. Menzel, Ph.D.Director · 8 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- Ali Behbahani, M.D.Director · 7 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Prakash Raman, Ph.D.Director · 1 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 16, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 18, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 24, 2024 | FY2023 |
| Annual report | 10-K | Mar 12, 2024 | FY2023 |
